机构:[1]Jilin Canc Hosp, Dept Thorac Oncol, Jilin, Peoples R China[2]Zhengzhou Univ, Affiliated Canc Hosp, Inst Canc Res, Dept Internal Med, Zhengzhou, Peoples R China河南省肿瘤医院[3]Henan Acad Innovat Med Sci, Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[4]Beijing Canc Hosp, Beijing, Peoples R China[5]Peking Univ Canc Hosp & Inst, Beijing, Peoples R China[6]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Dept Thorac Med Oncol,Xiangya Sch Med, Changsha, Peoples R China[7]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China[8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China[9]China Med Univ, Hosp 1, Shenyang, Peoples R China[10]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Affiliated Canc Hosp,Key Lab Sich, Chengdu, Peoples R China四川省肿瘤医院[11]Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China[12]Liaoning Canc Hosp, Shenyang, Liaoning, Peoples R China[13]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China[14]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[15]Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China[16]Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China[17]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[18]AstraZeneca, Shanghai, Peoples R China[19]AstraZeneca, New York, NY USA[20]Univ Amsterdam, Vrije Univ Amsterdam, Canc Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands
出处:
ISSN:
摘要:
Background: The global, phase III, double-blind ADRIATIC trial
(NCT03703297) assessed D ± tremelimumab (T) vs placebo (P) as
consolidation therapy for patients (pts) with LS-SCLC who had not
progressed after concurrent chemoradiotherapy (cCRT). At the first
interim analysis (data cutoff 15 Jan 2024), D significantly improved
overall survival (OS; hazard ratio [HR] 0.73 [95% CI 0.57–0.93]; p =
0.0104) and progression-free survival (PFS; HR 0.76 [95% CI 0.61–
0.95]; p = 0.0161) vs P; the D+T arm remained blinded. We report a
prespecified subgroup analysis of D vs P in pts enrolled in China.
第一作者机构:[1]Jilin Canc Hosp, Dept Thorac Oncol, Jilin, Peoples R China
推荐引用方式(GB/T 7714):
Cheng Y.,Wang Q.,Fang J.,et al.Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis[J].JOURNAL OF THORACIC ONCOLOGY.2025,20(3):
APA:
Cheng, Y.,Wang, Q.,Fang, J.,Shi, A.,Wu, L....&Senan, S..(2025).Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis.JOURNAL OF THORACIC ONCOLOGY,20,(3)
MLA:
Cheng, Y.,et al."Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis".JOURNAL OF THORACIC ONCOLOGY 20..3(2025)